New York, Jan 7, 2026, 18:54 EST — After-hours
- Thermo Fisher shares eased about 0.6% in late trading after a wide regular-session range
- Company launched a CorEvitas obesity registry and set a Jan. 13 slot at JPMorgan’s healthcare conference
- TD Cowen raised its price target to $696, saying the Q4 “bar is higher” after the recent rally
Thermo Fisher Scientific shares slipped about 0.6% in after-hours trading on Wednesday to $617.15, after swinging between $611.93 and $626.40 during the session.
The dip comes with the stock sitting near recent highs and the calendar tightening. Investors are staring at next week’s J.P. Morgan Healthcare Conference and Thermo Fisher’s quarterly results later this month, looking for a clean read on demand and the 2026 setup.
On Tuesday, the company said it enrolled the first patient in a new PPD CorEvitas obesity registry, a prospective study meant to collect “real-world evidence” — data drawn from routine care rather than controlled trials — on the long-term use and outcomes of obesity therapies. “The CorEvitas Obesity Registry represents a major step forward,” Leslie Harrold, vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries, said in the release. Business Wire
Thermo Fisher also said Chief Executive Marc Casper will present at the J.P. Morgan 2026 Healthcare Conference on Jan. 13 at 11:15 a.m. ET, with a webcast posted to the company’s investor site.
On the Street, TD Cowen raised its price target on Thermo Fisher to $696 from $654 and kept a Buy rating. A price target is a broker’s estimate of where a stock could trade over the next year. The firm said it adjusted targets across life science tools into the fourth quarter and warned the “bar is higher” for results after recent share rallies. TipRanks
Thermo Fisher has climbed sharply in the first week of the year, touching $628.08 on Tuesday and then closing Wednesday at $617.15.
Wednesday’s slip came as U.S. stocks weakened more broadly, with the S&P 500 and Dow ending lower. Thermo Fisher’s life-science tools peers Danaher and others also edged down on the day.
Still, the bigger swing factor sits ahead: results and guidance. Investors will listen for management’s view on demand from pharma and biotech customers, trends in the company’s lab instruments and consumables, and performance in its services businesses, including PPD. Any sign of softer spending or margin pressure could hit the stock, especially after the early-year run.
Next up: Casper’s Jan. 13 appearance at the JPMorgan healthcare conference, then Thermo Fisher’s quarterly report and conference call on Jan. 29.
Related articles: Biotechnology
